[Bevacizumab versus ranibizumab: a draw?].
E H
EH
Souied
S Y
SY
Cohen
L
L
Kodjikian
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D000069579:Ranibizumab; D016896:Treatment Outcome; D014481:United States; D014652:Vascular Diseases / Q000139:chemically induced / Q000453:epidemiology; D014792:Visual Acuity / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab